Generic Name and Formulations:
Insulin glulisine (rDNA origin) 100 Units/mL; contains m-cresol.
Indications for APIDRA:
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults).
Adults and Children:
<4yrs: not established. ≥4yrs: Give SC, either by injection or by external infusion pump. Rotate inj sites (abdomen, thigh, upper arm). SC inj: give 15mins before meal or within 20mins after starting meal; use with an intermediate or long-acting insulin. Or, may give by IV under medical supervision. Individualize; monitor and adjust as needed.
During episodes of hypoglycemia.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients. Monitor glucose, potassium levels (esp. by IV route). May need to adjust dose during infection, illness, stress, trauma, pregnancy. Monitor for heart failure. May need lesser dose with renal or hepatic dysfunction. Elderly. Pregnancy (Cat.C). Nursing mothers.
See full labeling. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by ACE inhibitors, oral antidiabetic agents, pramlintide, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics. Antagonized by corticosteroids, niacin, danazol, diuretics, sympathomimetics, glucagon, isoniazid, phenothiazines, somatropin, protease inhibitors, atypical antipsychotics, thyroid hormones, estrogens, progestogens. Hypoglycemia with pentamidine; may be followed by hyperglycemia. Variable effects with β-blockers, clonidine, lithium, alcohol. β-blockers, clonidine, guanethidine, and reserpine may mask hypoglycemia. Caution with K+-depleting drugs or those sensitive to serum potassium concentrations; may cause hypokalemia. Do not mix with insulins other than NPH; draw insulin glulisine into syringe first, inject immediately after mixing. Do not dilute or mix with other insulins in pump.
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, hypokalemia, weight gain, peripheral edema.
Vial (10mL)—1; Apidra SoloStar pen (3mL)—5 (prefilled, disposable inj device)
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV